Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 1

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 2Head & Neck 2Endocrine 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 69Lymphoma 20Lymphoma, Mantle-Cell 19Leukemia, Myeloid, Acute 17Leukemia, Lymphocytic, Chronic, B-Cell 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Non-Hodgkin 15Neoplasms, Plasma Cell 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Follicular 13Lymphoma, B-Cell, Marginal Zone 12Unspecified Adult Solid Tumor, Protocol Specific 10Hodgkin Disease 10Lymphoma, Large-Cell, Anaplastic 9Immunoblastic Lymphadenopathy 9Waldenstrom Macroglobulinemia 8Recurrence 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 8Burkitt Lymphoma 8Myelodysplastic Syndromes 7Lymphoma, T-Cell, Cutaneous 7Head and Neck Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sezary Syndrome 6Neoplasms 6Mycosis Fungoides 6Lymphoma, Large-Cell, Immunoblastic 6Congenital Abnormalities 6Breast Neoplasms 6

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Specimen Handling 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × Bortezomib × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT01078961 2016-06-08

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Massachusetts General Hospital

Phase 1 Completed
11 enrolled
Dermatologic

Melanoma

NCT01462773 2015-01-13

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
16 enrolled 5 charts
Dermatologic

Melanoma

NCT00667641 2011-05-10

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
16 enrolled
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡